Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's Tecentriq Steals Lead In Triple-Negative Breast Cancer

Executive Summary

The PD-L1 inhibitor is the first checkpoint immunotherapy to gain approval in the tough-to-treat disease setting.

Advertisement

Related Content

Roche's Tecentriq Becomes Second In PD-1/L1 Family To Gain First-Line Lung Cancer Approval
Roche Remains Positive After Tecentriq Triple-Negative Breast Cancer Data
Merck's Keytruda Offers Hope And Risk In Early Breast Cancer
Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval
Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124884

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel